Ras, ROS and Proteotoxic Stress: A Delicate Balance  by Xu, Wanping et al.
Cancer Cell
PreviewsRas, ROS and Proteotoxic Stress: A Delicate BalanceWanping Xu,1 Jane Trepel,2 and Len Neckers1,*
1Urologic Oncology Branch
2Medical Oncology Branch
National Cancer Institute, Center for Cancer Research, 9000 Rockville Pike, Bethesda, MD 20892, USA
*Correspondence: neckers@nih.gov
DOI 10.1016/j.ccr.2011.08.020
Ras-deregulated cells require reactive oxygen species for proliferation. They survive the resultant proteo-
toxic stress bymaintaining sufficient levels of reduced glutathione and optimally functioning stress response
machinery. In this issue of Cancer Cell, De Raedt et al. identify a novel strategy that utilizes this dependency
to cause cell death.The small GTPase protein Ras is tethered
to the plasma membrane and relays
signals from cell surface receptors to
cytosolic effectors in order to promote
cell growth and survival. When deregu-
lated by mutation or other means, Ras
proteins are crucial mediators of malig-
nant transformation (Downward, 2003).
Even though significant efforts have
been made for more than two decades
to develop Ras-targeted therapies, these
initiatives have proven less successful
than expected (Matallanas and Crespo,
2010). Moreover, Ras-driven tumors are
often highly aggressive and are resistant
to conventional chemotherapy, empha-
sizing the unmet need to identify novel
strategies to target this oncogene. In this
issue of Cancer Cell, De Raedt et al.
(2011) describe an effective strategy that
combines two drugs targeting different
molecules, the molecular chaperone heat
shock protein 90 (Hsp90) and the mam-
malian target of rapamycin (mTOR), to
induce catastrophic endoplasmic retic-
ulum (ER) stress by exploiting the depen-
dence of Ras-driven tumors on reactive
oxygen species (ROS).
Under normal conditions, Ras is acti-
vated when it is bound to GTP and
inactivated when its GTPase activity is
stimulated by proteins termed RasGAPs
(Ras-GTPase activating proteins), one of
which is the tumor suppressor NF1
(neurofibromatosis type 1). Somatic-inac-
tivating mutations of NF1 that result in
aberrant Ras activation have been found
in sporadic glioblastoma, non-small cell
lung cancer (NSCLC), and malignant
peripheral nerve sheath tumors (MPNSTs)
(Jett and Friedman, 2010). As a conse-
quence of Ras deregulation, mTOR is
activated in NF1-deficient tumors, andmTOR inhibitors such as rapamycin
suppress tumor growth in vitro but have
demonstrated only cytostatic activity
in vivo. While searching for agents to
enhance the efficacy of rapamycin, De
Raedt and colleagues found that ER-dis-
rupting reagents, such as tunicamycin
and thapsigargin, synergized with rapa-
mycin to induce the death of Ras-driven
cancer cells (but not of untransformed
cells). However, neither tunicamycin,
which interferes with protein glycosylation
in the ER, nor thapsigargin, which pro-
motes calcium release from the ER, are
clinically viable. De Raedt et al. found
that several Hsp90 inhibitors currently
undergoing extensive clinical evaluation
as anticancer drugs, including IPI-504
(retaspimycin), also were synergistic with
rapamycin. A previous study identified
the ER transmembrane kinases and
stress response effectors inositol requir-
ing enzyme-1 (IRE-1) and protein kinase
RNA-like endoplasmic reticulum kinase
(PERK) as Hsp90-dependent proteins
(Marcu et al., 2002). De Raedt et al.
confirm this earlier finding and further
confirm that Hsp90 inhibitors such as
IPI-504 abrogate a cell’s ability to mount
an effective ER response when faced
with severe proteotoxic stress.
A certain level of ER proteotoxic stress
is a common characteristic of cancer
cells, and is caused by a variety of factors
including hypoxia, oxidative stress, and
high mutational load. Thus, cancer cells
depend on optimal function of the cellular
stress response machinery, because
catastrophic ER stress causes cell death.
Unlike the reducing environment of the
cytosol, the ER provides a unique oxidiz-
ing environment that promotes formation
of protein disulfide bonds. AccumulatingCancer Cell 20, Seevidence indicates that ROS generation
is a byproduct of protein oxidation in the
ER. Since oxidative stress also induces
ER stress, persistent ROS elevation in
conjunction with compromised ER stress
response machinery initiates a vicious
cycle, leading to ER collapse and cell
death.
The dependence of Ras-driven cancers
on elevated ROS levels makes them
particularly sensitive to this strategy, as
shown by De Raedt et al. (2011). Impor-
tantly, ROS is required for Ras-depen-
dent cell proliferation. Ras deregulation
promotes tonic activation of the Raf-
MEK-ERK signal transduction cascade.
While low levels of ERK activation pro-
mote proliferation, high levels of acti-
vation result in growth arrest (Meloche
and Pouysse´gur, 2007). Thus, Ras-acti-
vated cancer cells must buffer the level
of ERK activation to be compatible with
proliferation, and they employ mitochon-
drial ROS for this purpose (see 1 in
Figure 1) (Weinberg et al., 2010). On the
other hand, the ROS level must be tightly
regulated, since too much oxidative
stress is harmful for the reasons de-
scribed above. Thus, Ras-driven cancers
are particularly dependent on maintaining
an appropriate but not excessive ROS
level. To achieve this balance, cancer
cells must maintain sufficient reducing
capability, which they accomplish in part
by metabolizing glucose via the pentose
phosphate pathway to generate NADPH
that in turn promotes accumulation of
reduced glutathione (GSH). Indeed, glu-
cose metabolism via the pentose phos-
phate pathway is essential for Ras-stimu-
lated growth under normoxic conditions
(Weinberg et al., 2010). The key enzyme
in this pathway is glucose 6-phosphateptember 13, 2011 ª2011 Elsevier Inc. 281
Figure 1. The Relationship between Ras-Driven Signaling Pathways, ROS, Hsp90, and ER
Stress
Ras-driven proliferation requires ROS buffering of Ras-activated ERK1/2 activity (1). ROS level is regulated
in part by reduced glutathione (GSH), requiring sufficient NADPH generated by G6PD-mediated glucose
oxidation via the pentose phosphate pathway (2). G6PD expression is regulated by mTOR, a component
of a second Ras-driven signaling pathway that is inhibited by rapamycin (3). Hsp90 buffers cellular ROS
and is essential for stabilization and activity of the ER transmembrane kinases PERK and IRE1, two
components of the ER stress response machinery. The Hsp90 inhibitor IPI-504 causes ROS levels to
increase while also abrogating the ER stress response (4). The combination of IPI-504 and rapamycin
disrupts the balance between ROS and GSH, causing catastrophic ER stress and cell death.
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Raedt and colleagues, G6PD is regulated
by mTOR, a component of a second
Ras-driven signaling pathway (Figure 1).
Thus, Ras-dependent mTOR activation
is essential to maintain sufficient levels
of reduced glutathione (see 2 in Figure 1).
It follows that inhibition of mTOR by
rapamycin interferes with an important
ROS-scavenging mechanism (see 3 in
Figure 1).
Hsp90 has been reported to buffer
cellular ROS in other systems, although
its mechanism of action remains poorly
understood (Yang et al., 2011). Neverthe-
less, these data support the observations
made by De Raedt and colleagues that
IPI-504 and other Hsp90 inhibitors in-
crease ROS in Ras-driven cancer cells
(see 4 in Figure 1). In addition to this
activity and its abrogation of a robust ER
stress response, Hsp90 inhibition also282 Cancer Cell 20, September 13, 2011 ª20suppresses mTOR signaling (Ohji et al.,
2006), explaining the current finding that
combined administration of rapamycin
and IPI-504 has a more dramatic impact
on G6PD expression and GSH levels in
MPNSTs in vivo than does either agent
alone. Further, these data are in agree-
ment with, and perhaps explain, the
underlying basis of a recent report that
Ras mutation in NSCLC confers en-
hanced dependence on Hsp90 (Sos
et al., 2009). De Raedt and colleagues
found that the cytotoxicity (both in vitro
and in vivo) of the Hsp90/mTOR inhibitor
combination was ameliorated by adminis-
tration of the ROS scavenger ascorbic
acid. This is certainly consistent with the
hypothesis that abrogation of the ER
stress response concomitantly with sup-
pression of ROS regulation is responsible
for the dramatic antitumor activity re-
ported. A clinical trial to evaluate the11 Elsevier Inc.activity of IPI-504 and the mTOR inhibitor
everolimus in Ras-mutated NSCLC is
currently enrolling patients (http://www.
infi.com/product-candidates-pipeline-ipi-
504.asp).
Simultaneous targeting of Hsp90 and
mTOR also demonstrates synergistic
activity in several other cancer models, in-
cluding hepatocellular carcinoma, breast
cancer, and multiple myeloma. It will be
intriguing to determine if a similar under-
lying mechanism involving ROS deregula-
tion and ER collapse pertains in these
cases. Given that increased oxidative
stress is characteristic of most cancers,
strategies to take advantage of this
common liability might help improve the
less than expected clinical activity of
Hsp90 inhibitors when used as single
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